Abu Dhabi inks MoU to enhance its role as a major pharmaceutical and life sciences distribution hub.
The Department of Health – Abu Dhabi (DoH), alongside the Abu Dhabi Investment Office (ADIO), Etihad Airways, and AD Ports Group, has signed a memorandum of understanding (MoU) aimed at bolstering Abu Dhabi’s status as a global hub for pharmaceutical and life sciences distribution. This strategic agreement was formalised during the BIO International Convention 2024 in California, USA.
Key signatories included Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at DoH; Stanislas Brun, Vice President of Etihad Cargo; and Mansoor Al Marar, Vice President of Industrial Business Development at KEZAD Group, a subsidiary of AD Ports Group.
Al Mannaei highlighted the MoU’s objective to attract pharmaceutical, biotechnology, and medical technology companies to Abu Dhabi, leveraging its strategic location and advanced infrastructure. She emphasised DoH’s commitment to transforming the regional healthcare ecosystem and improving healthcare outcomes through this initiative.
Badr Al-Olama, Director General of ADIO, underscored Abu Dhabi’s strategic focus on the healthcare and life sciences sectors, noting the city’s advanced infrastructure and supportive regulations. He emphasised that this partnership would drive further collaboration and innovation in the sector.
Stanislas Brun of Etihad Cargo reaffirmed the airline’s commitment to supporting Abu Dhabi’s vision, highlighting the MoU’s significance in enhancing the UAE’s role in the global pharmaceutical supply chain and improving access to innovative healthcare products for patients regionally and globally.
